ORCID Profile
0000-0002-2393-0855
Current Organisation
National University of Singapore
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: IEEE
Date: 06-2018
Publisher: AIP Publishing
Date: 12-2019
DOI: 10.1063/1.5126723
Abstract: One-shot information theory entertains a plethora of entropic quantities, such as the smooth max- ergence, hypothesis testing ergence, and information spectrum ergence, that characterize various operational tasks in quantum information theory and are used to analyze their asymptotic behavior. Tight inequalities between these quantities are thus of immediate interest. In this note, we use a minimax approach (appearing previously, for ex le, in the proofs of the quantum substate theorem), to simplify the quantum problem to a commutative one, which allows us to derive such inequalities. Our derivations are conceptually different from previous arguments and in some cases lead to tighter relations. We hope that the approach discussed here can lead to progress in open problems in quantum Shannon theory and exemplify this by applying it to a simple case of the joint smoothing problem.
Publisher: American Physical Society (APS)
Date: 09-11-2018
Publisher: Institute of Electrical and Electronics Engineers (IEEE)
Date: 12-2020
Publisher: Institute of Electrical and Electronics Engineers (IEEE)
Date: 08-2020
Publisher: Institute of Electrical and Electronics Engineers (IEEE)
Date: 04-2020
Publisher: Ovid Technologies (Wolters Kluwer Health)
Date: 05-10-2021
Abstract: In event‐driven clinical trials, study termination is based on accrual of a target number of primary efficacy events. For noninferiority trials in which superiority is conditionally examined, the ideal cohort in which to track event accrual is unclear. We used data from the ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial to determine the effect of primary efficacy‐event tracking in the per‐protocol cohort during the on‐treatment period versus the intention‐to‐treat (ITT) cohort during the ITT period. ROCKET AF was terminated after accruing 429 primary efficacy events (stroke or systemic embolism) in the per‐protocol cohort during the on‐treatment period for noninferiority. We identified the date on which 429 events occurred in the ITT cohort during the ITT period. We performed noninferiority and superiority analyses based on hypothetical study termination on this date. ROCKET AF would have terminated 226 days earlier if events were tracked during the ITT period. Similar to the main trial findings, rivaroxaban would have met noninferiority versus warfarin for the primary efficacy end point (hazard ratio [HR], 0.77 95% CI, 0.62–0.96 P .001). In contrast to the main trial findings, rivaroxaban would have met superiority for the primary efficacy end point (HR, 0.82 95% CI, 0.68–0.99 P =0.038). In both termination scenarios, rivaroxaban was associated with a lower risk of intracranial hemorrhage and similar risk of other safety end points. Clinical trial termination based on event accrual in the ITT cohort versus the per‐protocol cohort may have important implications on trial results depending on rates of study drug discontinuation and event rates off treatment.
Publisher: BMJ
Date: 27-01-2020
No related grants have been discovered for manesh patel.